Last reviewed · How we verify
Haemocomplettan® P or RiaSTAPTM
Haemocomplettan® P or RiaSTAPTM is a Biologic drug developed by Octapharma. It is currently in Phase 2 development. Also known as: Plasma derived fibrinogen concentrate.
At a glance
| Generic name | Haemocomplettan® P or RiaSTAPTM |
|---|---|
| Also known as | Plasma derived fibrinogen concentrate |
| Sponsor | Octapharma |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Haemocomplettan® P or RiaSTAPTM CI brief — competitive landscape report
- Haemocomplettan® P or RiaSTAPTM updates RSS · CI watch RSS
- Octapharma portfolio CI
Frequently asked questions about Haemocomplettan® P or RiaSTAPTM
What is Haemocomplettan® P or RiaSTAPTM?
Haemocomplettan® P or RiaSTAPTM is a Biologic drug developed by Octapharma.
Who makes Haemocomplettan® P or RiaSTAPTM?
Haemocomplettan® P or RiaSTAPTM is developed by Octapharma (see full Octapharma pipeline at /company/octapharma).
Is Haemocomplettan® P or RiaSTAPTM also known as anything else?
Haemocomplettan® P or RiaSTAPTM is also known as Plasma derived fibrinogen concentrate.
What development phase is Haemocomplettan® P or RiaSTAPTM in?
Haemocomplettan® P or RiaSTAPTM is in Phase 2.
Related
- Manufacturer: Octapharma — full pipeline
- Also known as: Plasma derived fibrinogen concentrate
- Compare: Haemocomplettan® P or RiaSTAPTM vs similar drugs
- Pricing: Haemocomplettan® P or RiaSTAPTM cost, discount & access